泽尼达妥单抗的副作用与注意事项

Zenidatuzumab is a bispecific antibody therapy for HER2-positive biliary tract cancer that inhibits tumor growth by blocking the HER2 signaling pathway and activating immune responses. Common side effects include gastrointestinal reactions, cardiac dysfunction and infusion-related reactions, which require strict monitoring and management. When using this drug, attention should be paid to pregnancy risks, cardiac function assessment, and medication restrictions for special populations. Despite certain side effects, zenidatuzumab provides a new treatment option for patients with HER2-high-expressing biliary tract cancer, with significant efficacy.

Side effects of zenidatuzumab

Zenidatuzumab may cause a variety of side effects during treatment, involving different organ systems. Patients need to understand these adverse reactions so that they can take timely response measures.

Common gastrointestinal reactions

Diarrhea and abdominal pain are the most common adverse reactions of zenidatumumab. Some patients may experience grade 3 or more severe diarrhea and need to suspend the medication and undergo anti-diarrhea treatment. If symptoms persist or worsen, the medication may need to be permanently discontinued.

Abnormal cardiac function

Zenidatuzumab may cause left ventricular dysfunction, manifested by decreased LVEF. Baseline LVEF needs to be assessed before treatment and monitored regularly during treatment. If LVEF drops significantly, the medication needs to be suspended and recovery evaluated, and if necessary, discontinued permanently.

Infusion-related reactions

Some patients may experience mild to severe infusion reactions during the infusion process. Mild reactions can be alleviated by reducing the infusion rate, while severe reactions require immediate discontinuation of the drug and symptomatic treatment. Pretreatment medications such as antihistamines and corticosteroids can reduce the risk.

The side effects of zenidatuzumab need to be managed through strict monitoring and dose adjustment to balance efficacy and safety.

Precautions for Zenidatuzumab

There are many precautions that need to be followed when using Zenidatuzumab.

Pregnancy risk

Zenidatuzumab may cause harm to the fetus and is contraindicated in pregnant women. Women of reproductive potential must take effective contraceptive measures during treatment and within 4 months after the last dose.

Cardiac function monitoring

Patients’ cardiac function needs to be evaluated before treatment, and patients with baseline LVEF lower than 50% should use with caution. Monitor LVEF regularly during treatment, and deal with any abnormality promptly.

Usage in special populations

The use data for children, the elderly and patients with liver and kidney damage are limited, and risks and benefits need to be carefully evaluated. Breastfeeding women should weigh the pros and cons of breastfeeding.

The risks of zenidatuzumab treatment can be minimized by strictly following the precautions.

The efficacy of zenidatuzumab

Zenidatuzumab provides a breakthrough treatment option for patients with HER2-positive biliary tract cancer, and its unique mechanism of action significantly improves the therapeutic effect.

Mechanism of action

Zenidatuzumab effectively inhibits tumor growth by simultaneously binding to two non-overlapping epitopes of the HER2 protein, blocking signal transduction and activating immune responses.

Clinical Indications

The drug is suitable for patients with previously treated unresectable or metastatic HER2-high-expressing biliary tract cancer, filling the gap in targeted therapy for such patients.

Therapeutic Advantages

As the world's first bispecific antibody therapy for HER2-positive biliary tract cancer, zenidatuzumab has significantly prolonged the progression-free survival of patients and improved their quality of life.

The efficacy of zenidatuzumab brings new hope to patients with biliary tract cancer, and its clinical value deserves further exploration.